1. Atypical Clinical Presentation of a Newer Generation Anti-Fungal Drug-Resistant Fusarium Infection After a Modified Multi-Visceral Transplant
- Author
-
Koji Hashimoto, Ahmed Kandeel, Ahmed Abd-Elaal, Mansiur Parsi, Ajai Khanna, Kareem Abu-Elmagd, Galal El-Gazzaz, Ana E. Bennett, Michael Spinner, and Masato Fujiki
- Subjects
Palate, Hard ,Fusariosis ,Fusarium ,medicine.medical_specialty ,Antifungal Agents ,Population ,Drug resistance ,Neutropenia ,Organ transplantation ,Immunocompromised Host ,Esophagus ,Fatal Outcome ,Drug Resistance, Fungal ,Amphotericin B ,Internal medicine ,medicine ,Humans ,Treatment Failure ,Intensive care medicine ,education ,Voriconazole ,Transplantation ,education.field_of_study ,biology ,business.industry ,Organ Transplantation ,General Medicine ,Middle Aged ,medicine.disease ,biology.organism_classification ,Female ,business ,medicine.drug - Abstract
BACKGROUND Fusarium spp. infections have become an emerging and lethal threat to the immunocompromised patient population, especially those with neutropenia. Recently there have been increased reports in solid organ transplant recipients. Presentation is commonly as soft tissue infections several months post-transplant. With high morbidity and mortality, efficacious antifungal therapy is essential. This remains challenging with limited data and no established clinical breakpoints defined. CASE REPORT We report on a modified multi-visceral transplant patient that developed a Fusarium infection only 7 weeks post-transplant in the native hard palate and esophagus, without any soft tissue lesions, which persisted despite aggressive combination treatment with amphotericin B lipid complex and voriconazole. CONCLUSIONS Fusarium spp. infection in solid organ transplant is a significant challenge without clear diagnostic clinical indicators of infection, or specific time of onset, in addition to possible emergence of a more aggressive drug-resistant strain.
- Published
- 2015